| First Author | Morii M | Year | 2024 |
| Journal | Leukemia | Volume | 38 |
| Issue | 6 | Pages | 1275-1286 |
| PubMed ID | 38734786 | Mgi Jnum | J:352280 |
| Mgi Id | MGI:7705790 | Doi | 10.1038/s41375-024-02276-w |
| Citation | Morii M, et al. (2024) TIF1beta activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia. Leukemia 38(6):1275-1286 |
| abstractText | TIF1beta/KAP1/TRIM28, a chromatin modulator, both represses and activates the transcription of genes in normal and malignant cells. Analyses of datasets on leukemia patients revealed that the expression level of TIF1beta was increased in patients with chronic myeloid leukemia at the blast crisis and acute myeloid leukemia. We generated a BCR::ABL1 conditional knock-in (KI) mouse model, which developed aggressive myeloid leukemia, and demonstrated that the deletion of the Tif1beta gene inhibited the progression of myeloid leukemia and showed longer survival than that in BCR::ABL1 KI mice, suggesting that Tif1beta drove the progression of BCR::ABL1-induced leukemia. In addition, the deletion of Tif1beta sensitized BCR::ABL1 KI leukemic cells to dasatinib. The deletion of Tif1beta decreased the expression levels of TIF1beta-target genes and chromatin accessibility peaks enriched with the Fosl1-binding motif in BCR::ABL1 KI stem cells. TIF1beta directly bound to the promoters of proliferation genes, such as FOSL1, in human BCR::ABL1 cells, in which TIF1beta and FOSL1 bound to adjacent regions of chromatin. Since the expression of Fosl1 was critical for the enhanced growth of BCR::ABL1 KI cells, Tif1beta and Fosl1 interacted to activate the leukemic transcriptional program in and cellular function of BCR::ABL1 KI stem cells and drove the progression of myeloid leukemia. |
